Headache

Introducing Snufff: Your Pocket-Sized Lifestyle Companion

Retrieved on: 
Friday, April 19, 2024
Mint, Coffee, Health, Adventure, Headache, Smoke, Life

SINGAPORE, April 19, 2024 /PRNewswire/ -- Snufff, the innovative nasal inhaler, emerges onto the wellness and lifestyle scene, offering a refreshing blend of enjoyment and health benefits.

Key Points: 
  • SINGAPORE, April 19, 2024 /PRNewswire/ -- Snufff, the innovative nasal inhaler, emerges onto the wellness and lifestyle scene, offering a refreshing blend of enjoyment and health benefits.
  • Crafted in the vibrant heart of Singapore, Snufff aims to revolutionize the way we approach personal well-being.
  • "Why subject our health to unnecessary harm when we can enjoy the same benefits with a product that's all about fun and zero health risks?"
  • More than just a product, Snufff represents a lifestyle companion seamlessly integrated into daily routines.

GUNNAR Optiks Reveals Clear Pro Lenses - Offering Blue-Light Blocking Benefits With Perfect Color Rendition

Retrieved on: 
Wednesday, April 17, 2024
Amazon (company), Gunnar Optiks, Carbon, Blinking, Entrepreneurship, Lens, GLARE, Headache, Fatigue, Wood, Circadian rhythm, Melatonin, Computer vision syndrome, Camera

CARLSBAD, Calif., April 17, 2024 /PRNewswire/ -- GUNNAR Optiks, the preeminent manufacturer and pioneer of premium computer eyewear, today announced that it is shifting the market paradigm it helped pioneer nearly 20 years ago and reinventing computer glasses to offer perfect color rendition. Enter Clear Pro lens technology, designed for creative professionals. In today's digitally driven world, seeing in true color is paramount for creative professionals and Clear Pro represents 10 years of optical research into creating the ideal lens for unparalleled color accuracy with the benefits of reducing digital eye strain and preventing computer vision syndrome symptoms.

Key Points: 
  • Similar to a neutral-density camera lens filter, Clear Pro lenses reduce the amount of light passing through the lens without changing or skewing the color of light passing through.
  • Developed based on requests from visual creatives who loved the many benefits GUNNAR glasses offered, but were unable to wear them for critical tasks where perfect color rendition was required, Clear Pro fills the void, allowing creatives to see in perfect color while reducing blue light exposure by 20%.
  • The technology represents over 10 years of optical research in color rendition, digital eye strain, and visual ergonomics to design the best lenses for creative professionals.
  • GUNNAR is the only patented gaming and computer eyewear recommended by doctors to protect and enhance your vision.

InventHelp Inventor Develops Massage Device to Relieve Headaches (ACC-240)

Retrieved on: 
Tuesday, April 16, 2024
Relaxation, Migraine, Sale, Pain, Suite, Massage, HEAD, Headache, Multimedia, Anxiety

PITTSBURGH, April 16, 2024 /PRNewswire/ -- "I thought there should be a hands-free way to massage the head to help relieve headache pain," said an inventor, from Loganville, Ga., "so I invented the HEAD, FOREHEAD, AND TEMPLE RELIEVER MASSAGER.

Key Points: 
  • PITTSBURGH, April 16, 2024 /PRNewswire/ -- "I thought there should be a hands-free way to massage the head to help relieve headache pain," said an inventor, from Loganville, Ga., "so I invented the HEAD, FOREHEAD, AND TEMPLE RELIEVER MASSAGER.
  • My design increases relaxation and comfort by quickly alleviating the pain and other symptoms associated with various types of headaches."
  • The patent-pending invention provides an effective means to relieve headaches.
  • In doing so, it helps diminish pain associated with minor headaches to intense migraines.

Introducing TrueCall: The First Comprehensive System for Verifying Inbound Phone Calls

Retrieved on: 
Monday, April 15, 2024
Acquisition, Privacy, Marketing, CCPA, Ecosystem, Headache, GDPR, Risk, VCAP, Fraud, AI, Sales

NEWARK, Del., April 15, 2024 /PRNewswire/ - Today, TrueCall launches the first comprehensive system for verifying inbound phone calls from webpages, helping to protect businesses from the growing threat of fraudulent and non-compliant marketing tactics.

Key Points: 
  • NEWARK, Del., April 15, 2024 /PRNewswire/ - Today, TrueCall launches the first comprehensive system for verifying inbound phone calls from webpages, helping to protect businesses from the growing threat of fraudulent and non-compliant marketing tactics.
  • "Inbound calls are an incredibly valuable tool for businesses in augmenting their marketing efforts.
  • However, the potential for receiving non-compliant outbound calls poses significant risks," says Leonardo Danconia, Co-Founder of TrueCall.
  • Reduces the risk of non-compliant outbound calls, unauthorized inbound calls, fraudulent calls, consumer complaints, and associated liability.

NYU Langone Neurologists Present Latest Clinical Findings & Research at AAN 2024

Retrieved on: 
Saturday, April 13, 2024
Neuroimaging, American Academy, Brain, MCI, Stroke, White matter, Risk, Professor, News, NYU Langone Health, Doctor of Philosophy, Research, Appreciation, NYU, Deficit spending, Patient, AAN, Neurosurgery, Headache, Prevalence, MRI, Job satisfaction, Faculty, DSM-IV codes, Philip, Traumatic brain injury, Migraine, Practice, Biomarker, Annual general meeting, Organization, Growth, Medical imaging

DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.

Key Points: 
  • DENVER, April 13, 2024 /PRNewswire/ -- Experts from NYU Langone's Department of Neurology present their latest clinical findings and research discoveries at the American Academy of Neurology (AAN) 2024 Annual Meeting, April 13 to 18, in Denver.
  • U.S. News & World Report's "Best Hospitals" ranks NYU Langone the No.
  • Researchers at NYU Langone surveyed 90 clinicians, residents, and fellows to identify the best methods of showing neurologists that they are valued in order to improve their job satisfaction and reduce burnout.
  • Further research is warranted to validate these findings and their potential to enhance early detection and intervention strategies for Alzheimer's disease.

EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING

Retrieved on: 
Friday, April 12, 2024
Amyloid, Angioedema, Brain, Anticoagulant, Neuroimaging, Patient, Vascular malformation, Lecanemab, Siderosis, Dementia, Cell, Seizure, ARIA, Risk, Aspirin, Focal neurologic signs, Nausea, Cerebral edema, Dizziness, Paracetamol, Arthralgia, Cerebral amyloid angiopathy, Effectiveness, Genetic testing, Intraparenchymal hemorrhage, Observation, Confusion, Alzheimer's disease, Intracerebral hemorrhage, Status epilepticus, Vomiting, Incidence, Aneurysm, Anaphylaxis, Headache, Hypersensitivity, Hypertension, MRI, Magnetic resonance imaging, Chills, Neuron, Bronchospasm, Fatal, Hypotension, Tissue plasminogen activator, Edema, Fever, Excipient, Pharmaceutical industry

Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.

Key Points: 
  • Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA.
  • Depending on ARIA severity, use clinical judgment in considering whether to continue dosing, temporarily discontinue treatment, or permanently discontinue LEQEMBI.
  • There is no experience in patients who continued dosing through symptomatic ARIA-E or through asymptomatic, but radiographically severe, ARIA-E.
  • There is limited experience in patients who continued dosing through asymptomatic but radiographically mild to moderate ARIA-E.

AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

Retrieved on: 
Friday, April 12, 2024
Patient, ABBV, Safety, AbbVie, MD, Migraine, Freedom, European, Disease, Week, CGRP, Anesthesia, Neurology, Headache, PROGRESS, Harvard Medical School, Interim, Pharmaceutical industry

NORTH CHICAGO, Ill., April 12, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcomes, including reduction in monthly acute medication use days.

Key Points: 
  • The overall long-term safety results were consistent with the known safety profile of atogepant in chronic and episodic migraine, and no new safety signals were identified.
  • These results also support improvements in key efficacy outcomes, including reduction in monthly acute medication use days.
  • Overall safety results were consistent with the known safety profile of atogepant 60 mg, and no new safety signals were identified.
  • "Patients should accept nothing less than migraine freedom, and the long-term safety and efficacy shown in this interim analysis marks another step toward that goal."

MigraKet® Brings the World's First Medical Food For Migraine to the U.S

Retrieved on: 
Friday, April 12, 2024
Migraine, Pain, Woman, Doctor of Philosophy, Vitamin, Dehydration, Oxygen, Food, Headache, Metabolism, Antioxidant, Sleep, Injection

BASEL, Switzerland, April 12, 2024 /PRNewswire/ -- International wellness brand Brain Ritual is launching MigraKet®, a revolutionary approach to migraine management developed by renowned neuroscientist and former chronic migraineur, Elena Gross, PhD. With the U.S. release of MigraKet®, sufferers of migraine can anticipate a newfound hope in managing their condition effectively.

Key Points: 
  • With the U.S. release of MigraKet®, sufferers of migraine can anticipate a newfound hope in managing their condition effectively.
  • Different from drugs, painkillers and injections that address migraine symptoms, MigraKet® is the first holistic medical food formulation for the management of a potential root cause of migraine.
  • "We want migraine sufferers to regard their pain as a helpful alarm - alerting them of a critical system breakdown.
  • Chronic migraine is defined as having headache on at least 15 days per month, with eight of these having migraine symptoms, for at least three months.

Dr. Goodyear, Integrative Cancer Expert, Observes Benefits When Using CBD IV Therapy by Pico IV with Oncology Patients

Retrieved on: 
Wednesday, April 10, 2024
Pain, Brain, Jarisch–Herxheimer reaction, Blood pressure, Nausea, Diabetes, Bone metastasis, Embolism, Depression, Seizure, Obesity, Blood, Patient, Liver, Headache, Hypertension, Chills, Infection, Cannabidiol, Thrombosis, Fever, Anxiety, Medical device

SCOTTSDALE, Ariz., April 10, 2024 /PRNewswire/ -- Medical director of an integrative oncology center in Scottsdale, AZ, Nathan Goodyear, MD, MD(H), began using CBD IV Therapy by Pico IV over four months ago with cancer patients under his care.

Key Points: 
  • SCOTTSDALE, Ariz., April 10, 2024 /PRNewswire/ -- Medical director of an integrative oncology center in Scottsdale, AZ, Nathan Goodyear, MD, MD(H), began using CBD IV Therapy by Pico IV over four months ago with cancer patients under his care.
  • He found that CBD IV therapy was well-tolerated by almost all patients, with only two experiencing a Jarisch-Herxheimer reaction due to undiagnosed port infections.
  • Pico IV are the makers of the world's first CBD IV therapy.
  • Joe Young, CEO of Pico IV Inc, shared "When we first launched CBD IV Therapy, we were excited about the potential benefits for users.

Avulux Welcomes More Than 200 Eye Care Clinics Nationwide to its Authorized Provider Program for Migraine & Light Sensitivity Lenses

Retrieved on: 
Wednesday, April 10, 2024
Woman, DSM-IV codes, Nausea, Human, Migraine, Lens, Photophobia, Patient, Headache

As this network continues to grow, Avulux lenses have already made a positive impact on nearly 15,000 individuals experiencing migraine and light sensitivity.

Key Points: 
  • As this network continues to grow, Avulux lenses have already made a positive impact on nearly 15,000 individuals experiencing migraine and light sensitivity.
  • "The intersection of migraine and light sensitivity is an area where eye care professionals can make a significant difference in their patients' lives," said Dr. Charles Posternack, CEO and Co-Founder of Avulux.
  • "The growing number of ECPs joining our Avulux Authorized Provider program underscores their commitment to addressing photophobia and enhancing patient well-being."
  • By offering Avulux lenses, expanding practices become a vital resource for patients living with migraine and light sensitivity.